+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), By End-use, By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 100 Pages
  • July 2024
  • Region: North America
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5988586
The North America Skin Cancer Diagnostics Market is projected to witness market growth of 4.8% CAGR during the forecast period (2024-2031).

The US market dominated the North America Skin Cancer Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $3.35 billion by 2031. The Canada market is experiencing a CAGR of 7% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 6.1% during (2024 - 2031).



Technological advancements have profoundly impacted the skin cancer diagnostics market. The accuracy and efficacy of skin cancer detection have been improved by advancements in molecular diagnostics, artificial intelligence (AI), and imaging technologies.

Moreover, dermatoscopy, a non-invasive technique that uses a handheld device to examine skin lesions, has become a standard tool in dermatological practice. Confocal microscopy and high-frequency ultrasound offer detailed imaging at a cellular level, allowing for precise characterization of suspicious lesions.

In North America, the prevalence of skin cancer, particularly melanoma, is consistently increasing. This fuels the demand for accurate and efficient diagnostic tools. The United States has seen a significant rise in skin cancer cases, particularly melanoma, which is one of the most common types of cancer in the country. According to the American Cancer Society, about 100,640 new cases of melanoma are expected to be diagnosed in 2024, with approximately 8,290 deaths expected from the disease Factors contributing to the increased demand for skin cancer diagnostics include higher awareness and screening, increased exposure to ultraviolet (UV) radiation, and indoor tanning practices.

List of Key Companies Profiled

  • Castle Biosciences, Inc.
  • Bausch Health Companies, Inc. (DermTech, Inc.)
  • Canfield Scientific, Inc.
  • DermaSensor, Inc.
  • F.Hoffmann-La Roche Ltd.
  • NeoGenomics, Inc.
  • Quest Diagnostics Incorporated.
  • Digital Diagnostics, Inc. (3Derm Systems, Inc.)
  • FotoFinder Systems GmbH
  • Veriskin Inc

Market Report Segmentation

By Type
  • Non-Melanoma
  • Melanoma
By Test Type
  • Skin Biopsy
  • Imaging Tests
  • Dermatoscopy
  • Lymph Node Biopsy
  • Others
By End-use
  • Hospital & Clinics
  • Laboratories
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Skin Cancer Diagnostics Market, by Type
1.4.2 North America Skin Cancer Diagnostics Market, by Test Type
1.4.3 North America Skin Cancer Diagnostics Market, by End-use
1.4.4 North America Skin Cancer Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. North America Skin Cancer Diagnostics Market by Type
4.1 North America Non-Melanoma Market by Country
4.2 North America Melanoma Market by Country
Chapter 5. North America Skin Cancer Diagnostics Market by Test Type
5.1 North America Skin Biopsy Market by Country
5.2 North America Imaging Tests Market by Country
5.3 North America Dermatoscopy Market by Country
5.4 North America Lymph Node Biopsy Market by Country
5.5 North America Others Market by Country
Chapter 6. North America Skin Cancer Diagnostics Market by End-use
6.1 North America Hospital & Clinics Market by Country
6.2 North America Laboratories Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Skin Cancer Diagnostics Market by Country
7.1 US Skin Cancer Diagnostics Market
7.1.1 US Skin Cancer Diagnostics Market by Type
7.1.2 US Skin Cancer Diagnostics Market by Test Type
7.1.3 US Skin Cancer Diagnostics Market by End-use
7.2 Canada Skin Cancer Diagnostics Market
7.2.1 Canada Skin Cancer Diagnostics Market by Type
7.2.2 Canada Skin Cancer Diagnostics Market by Test Type
7.2.3 Canada Skin Cancer Diagnostics Market by End-use
7.3 Mexico Skin Cancer Diagnostics Market
7.3.1 Mexico Skin Cancer Diagnostics Market by Type
7.3.2 Mexico Skin Cancer Diagnostics Market by Test Type
7.3.3 Mexico Skin Cancer Diagnostics Market by End-use
7.4 Rest of North America Skin Cancer Diagnostics Market
7.4.1 Rest of North America Skin Cancer Diagnostics Market by Type
7.4.2 Rest of North America Skin Cancer Diagnostics Market by Test Type
7.4.3 Rest of North America Skin Cancer Diagnostics Market by End-use
Chapter 8. Company Profiles
8.1 Castle Biosciences, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Product Launches and Product Expansions:
8.1.4.2 Acquisition and Mergers:
8.1.5 SWOT Analysis
8.2 Bausch Health Companies, Inc.(DermTech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Canfield Scientific, Inc.
8.3.1 Company Overview
8.3.2 SWOT Analysis
8.4 DermaSensor, Inc.
8.4.1 Company Overview
8.4.2 SWOT Analysis
8.5 F. Hoffmann-La Roche Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.6 SWOT Analysis
8.6 Neogenomics, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Quest Diagnostics Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Recent strategies and developments:
8.7.4.1 Partnerships, Collaborations, and Agreements:
8.7.4.2 Acquisition and Mergers:
8.7.5 SWOT Analysis
8.8 Digital Diagnostics, Inc.(3Derm Systems, Inc.)
8.8.1 Company Overview
8.9 FotoFinder Systems GmbH
8.9.1 Company Overview
8.9.2 SWOT Analysis
8.10. VERISKIN INC.
8.10.1 Company Overview
8.10.2 SWOT Analysis

Companies Mentioned

  • Castle Biosciences, Inc.
  • Bausch Health Companies, Inc. (DermTech, Inc.)
  • Canfield Scientific, Inc.
  • DermaSensor, Inc.
  • F. Hoffmann-La Roche Ltd.
  • NeoGenomics, Inc.
  • Quest Diagnostics Incorporated.
  • Digital Diagnostics, Inc. (3Derm Systems, Inc.)
  • FotoFinder Systems GmbH
  • Veriskin Inc

Methodology

Loading
LOADING...